Korean mistletoe (Viscum album)

Tier 3 — weak evidence · Cancer adjunct · Immunity · Quality of life

European and Korean mistletoe extracts are widely prescribed in European integrative oncology, particularly in Germany and Switzerland. A 2024 review of 26 trials found mistletoe therapy significantly improves quality of life and reduces chemotherapy side effects in cancer patients. Used as an injection, not oral supplement. Generally well tolerated but can cause local injection reactions and fever.

Dose: Subcutaneous injection only (mistletoe extracts e.g., Iscador, Helixor: 1–20 mg per injection, 2–3×/week, dose-titrated by trained integrative oncology practitioner). Oral preparations are not effective for cancer indications.